Insmed is a global biopharmaceutical company developing first- and best-in-class therapies for serious respiratory, immunologic, inflammatory, and neurological diseases. The company commercializes approved products including ARIKAYCE, an inhaled liposomal formulation of amikacin for nontuberculous mycobacterial lung infections, and BRINSUPRI, an oral DPP1 inhibitor for non-cystic fibrosis bronchiectasis, while advancing a clinical pipeline of inhaled and gene therapy candidates in pulmonary, immunological, and rare neurological indications. Insmed generates revenue through direct commercialization of approved therapies in major markets and partnerships for manufacturing and distribution, with intellectual property protection extending across its marketed and developmental products.